We'll hopefully RVX can get it in gear.  They could perhaps have an edge in that Apabetalone has a proven safety record and perhaps the 2 prong therapeutic approach (but I certainly don't know enough about the science of Apabetalone or the PFE drug (a protease inhibitor) to do even a basic comparison - leave that to the science folks).

Of course the RVX disadvantage is as always crappy management, the glacial pace the company moves at is truly astonishing, especially in the context of CoVid.